Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 20, Issue 4, pp. 625-631
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 27, 2020
- Revision received November 5, 2020
- Accepted January 8, 2021
- Published first April 2, 2021.
Copyright & Usage
©2021 American Association for Cancer Research.
Author Information
- Joel Morris1,*,
- Donn G. Wishka1,
- Omar D. Lopez1,
- Vladimir Rudchenko2,
- Guangfei Huang2,
- Sierra N. Hoffman3,
- Suzanne Borgel3,
- Kyle Georgius3,
- John Carter3,
- Howard Stotler3,
- Mark W. Kunkel1,
- Jerry M. Collins1,
- Melinda G. Hollingshead1, and
- Beverly A. Teicher1
- 1Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
- 2Alchem Laboratories Corporation, Alachua, Florida.
- 3Leidos Biomedical Laboratories, FNLCR, Frederick, Maryland.
- ↵*Corresponding Author:
Joel Morris, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20852. Phone: 240-276-5953; Fax: 240-276-7895; E-mail: joel.morris{at}nih.gov
April 2021
Volume 20, Issue 4
Volume 20, Issue 4
F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd
Jump to section
Advertisement